Post-COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients.
Post-COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients.
复制标题
DOI：
10.1016/j.cmi.2022.03.016
复制
发表时间：
2022-08
期刊：
影响因子：
--
通讯作者：
Tascini C
中科院分区：
文献类型：
--
作者：
Peghin M;De Martino M;Palese A;Gerussi V;Bontempo G;Graziano E;Visintini E;D'Elia D;Dellai F;Marrella F;Fabris M;Curcio F;Sartor A;Isola M;Tascini C
本研究旨在描述SARS冠状病毒2型（CoV-2）发病1年后接种疫苗的影响和体液应答对COVID-19后综合征的作用。这项前瞻性研究通过访谈进行，以调查乌迪内医院（2020年3月至5月）所有成年COVID-19住院和门诊患者发病后6个月和12个月的COVID-19后综合征。还评估了疫苗接种状态和两种不同的血清学试验，以区分对疫苗接种（受体结合域（RBD）SARS-CoV-2 IgG）和/或自然感染（非RBD-SARS-CoV-2 IgG）的应答。在急性感染后13.5个月（标准差：0.6个月），共对479例患者（52.6%女性;平均年龄：53岁）进行了访谈。47.2%的患者（n = 226）在1年后观察到COVID-19后综合征。在接种疫苗（n = 132）和未接种疫苗（n = 347）的患者中，COVID-19后症状的恶化没有显著差异（22.7%对15.8%; p = 0.209）。自然感染诱导的非RBD SARS-CoV-2 IgG的存在与COVID-19后综合征显著相关（OR：1.35; 95% CI：1.11-1.64; p = 0.003），长途运输者的非RBD SARS-CoV-2 IgG滴度中位数显著高于无症状患者（22 kAU/L（四分位距，9.7 - 37.2 kAU/L）vs. 14.1 kAU/L（四分位距，5.4 - 31.3 kAU/L）; p = 0.009）。相反，RBD SARS-CoV-2 IgG的存在与COVID-19后综合征的发生无关（> 2500 U/mL vs. 0.9 - 2500 U/mL; OR：1.36; 95% CI，0.62 - 3.00; p = 0.441），RBD SARS-CoV-2 IgG滴度在长途运输者中与无症状患者相似（50%值> 2500 U/mL对比55.6%值> 2500 U/mL; p = 0.451）。SARS-CoV-2疫苗接种与急性感染后超过1年出现COVID-19后症状无关。由自然感染而非疫苗接种诱导的高血清学滴度反应的持续性可能在长期COVID-19中发挥作用。
This study aimed to describe the impact of vaccination and the role of humoral responses on post–COVID-19 syndrome 1 year after the onset of SARS coronavirus type 2 (CoV-2). This prospective study was conducted through interviews to investigate post–COVID-19 syndrome 6 and 12 months after disease onset in all adult in- and outpatients with COVID-19 at Udine Hospital (March–May 2020). Vaccination status and two different serological assays to distinguish between response to vaccination (receptor-binding domain (RBD) SARS-CoV-2 IgG) and/or natural infection (non-RBD-SARS-CoV-2 IgG) were also assessed. A total of 479 patients (52.6% female; mean age: 53 years) were interviewed 13.5 months (standard deviation: 0.6 months) after acute infection. Post–COVID-19 syndrome was observed in 47.2% of patients (n = 226) after 1 year. There were no significant differences in the worsening of post–COVID-19 symptoms (22.7% vs. 15.8%; p = 0.209) among vaccinated (n = 132) and unvaccinated (n = 347) patients. The presence of non-RBD SARS-CoV-2 IgG induced by natural infection showed a significant association with post–COVID-19 syndrome (OR: 1.35; 95% CI, 1.11–1.64; p = 0.003), and median non-RBD SARS-CoV-2 IgG titres were significantly higher in long haulers than in patients without symptoms (22 kAU/L (interquartile range, 9.7–37.2 kAU/L) vs. 14.1 kAU/L (interquartile range, 5.4–31.3 kAU/L); p = 0.009) after 1 year. In contrast, the presence of RBD SARS-CoV-2 IgG was not associated with the occurrence of post–COVID-19 syndrome (>2500 U/mL vs. 0.9–2500 U/mL; OR: 1.36; 95% CI, 0.62–3.00; p = 0.441), and RBD SARS-CoV-2 IgG titres were similar in long haulers as in patients without symptoms (50% values > 2500 U/mL vs. 55.6% values > 2500 U/mL; p = 0.451). The SARS-CoV-2 vaccination is not associated with the emergence of post–COVID-19 symptoms more than 1 year after acute infection. The persistence of high serological titre response induced by natural infection, but not vaccination, may play a role in long-haul COVID-19.
登录
查看更多内容
影响因子：
7.8
作者：
Strain, William David;Sherwood, Ondine;Banerjee, Amitava;Van der Togt, Vicky;Hishmeh, Lyth;Rossman, Jeremy
通讯作者：
Rossman, Jeremy
影响因子：
7.8
作者：
Gerussi V;Peghin M;Palese A;Bressan V;Visintini E;Bontempo G;Graziano E;De Martino M;Isola M;Tascini C
通讯作者：
Tascini C
住院和非医院患者急性感染后6个月后，旋转后-19症状。
DOI：
10.1016/j.cmi.2021.05.033
发表时间：
2021-10
期刊：
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子：
--
作者：
Peghin M;Palese A;Venturini M;De Martino M;Gerussi V;Graziano E;Bontempo G;Marrella F;Tommasini A;Fabris M;Curcio F;Isola M;Tascini C
通讯作者：
Tascini C
DOI：
10.1016/s2213-2600(21)00286-1
发表时间：
2021-12
期刊：
The Lancet. Respiratory medicine
影响因子：
--
作者：
Adeloye D;Elneima O;Daines L;Poinasamy K;Quint JK;Walker S;Brightling CE;Siddiqui S;Hurst JR;Chalmers JD;Pfeffer PE;Novotny P;Drake TM;Heaney LG;Rudan I;Sheikh A;De Soyza A;International COVID-19 Airways Diseases Group
通讯作者：
International COVID-19 Airways Diseases Group
DOI：
10.15585/mmwr.mm7044e1
发表时间：
2021-11-05
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Bozio CH;Grannis SJ;Naleway AL;Ong TC;Butterfield KA;DeSilva MB;Natarajan K;Yang DH;Rao S;Klein NP;Irving SA;Dixon BE;Dascomb K;Liao IC;Reynolds S;McEvoy C;Han J;Reese SE;Lewis N;Fadel WF;Grisel N;Murthy K;Ferdinands J;Kharbanda AB;Mitchell PK;Goddard K;Embi PJ;Arndorfer J;Raiyani C;Patel P;Rowley EA;Fireman B;Valvi NR;Griggs EP;Levy ME;Zerbo O;Porter RM;Birch RJ;Blanton L;Ball SW;Steffens A;Olson N;Williams J;Dickerson M;McMorrow M;Schrag SJ;Verani JR;Fry AM;Azziz-Baumgartner E;Barron M;Gaglani M;Thompson MG;Stenehjem E
通讯作者：
Stenehjem E